John D.
Scott
MD
MSc
FIDSA
related links
bio
In 2009, Dr Scott launched Project ECHO (Extension for Community Health Outcomes) in Washington State, the first place to replicate the ECHO model outside of New Mexico. This innovative telehealth program helps clinicians serving in rural and underserved areas with the evaluation and treatment of common, complex, chronic diseases. In 2015, he won the Warren Reid Award for excellence in health care for the state of Washington, in recognition of his telehealth work. He chairs the Washington State Telehealth Collaborative and serves on the Telehealth committee for the Infectious Disease Society of America. The Washington State Medical Association recognized him with the Grassroots Advocate Award in 2020 for his work in advocating for policy changes for telemedicine at the state and federal level.
research interests
- viral hepatitis
- solid organ transplantation and infections
- telemedicine and digital health
clinical interests
- viral hepatitis
- telemedicine
honors
Dr Scott graduated from Stanford University with a degree in Human Biology, attended Georgetown University School of Medicine cum laude, completed a residency in Internal Medicine at Stanford University Hospitals, and then obtained sub-specialty training in Infectious Diseases at the University of Washington. He joined the University of Washington faculty in 2005.
Honors
cum laude and Alpha Omega Alpha, Georgetown University School of Medicine
Warren Featherstone Reid Award
Best Doctors, Seattle Met
publications
1. Owens DK, Holodniy M, Garber AM, Scott J, Sonnad S, Moses L, Kinosian B, Schwartz JS. Polymerase chain reaction for the diagnosis of HIV infection in adults: A meta-analysis with recommendations for clinical practice and study design. Ann Intern Med 1996; 124:803-815.[original work]
2. Owens DK, Holodniy M, McDonald T, Scott J, Sonnad S. A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants. JAMA 1996; 275: 1342-8. [original work]
3. Nonnenmacher B, Kjaer SK, Svare EI, Scott JD, Hubbert NL, van den Brule AJ, Kirnbauer R, Walboomers JM, Lowy DR, Schiller JT. Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations. Int J Cancer 1996; 68: 704-9. [original work]
4. Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. Clin Infect Dis 2005; 41: 1677-80. [original work]
5. Scott JD, McMahon BJ, Bruden D, Sullivan DG, Homan C, Christensen C, Gretch DR. Spontaneous HCV RNA negativity after establishment of chronic infection in Alaska Natives. Clin Infect Dis 2006; 42: 945-952. [original work]
6. Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: A systematic review. JAMA 2007; 297: 724-732. [review]
7. Limaye A, Boudreault A, Rakita R, Scott J, Boeckh M, Davis C. Risk Factors for Late-Onset Cytomegalovirus (CMV) Disease in Donor Seropositive/Recipient Seronegative (D+R-) Kidney Transplant Recipients who Receive Antiviral Prophylaxis. Transplant Infect Dis 2011; 13:244-9. [original work]
8. Scott JD, Holte S, Urban T, Burgess C, Coppel E, Wang C, Corey L, McHutchison J, Goldstein D. IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult to treat hepatitis C virus infection. J Infect Dis 2011; 204:419-25. [original work]
9. Scott J, Unruh K, Catlin MC, Merrill JO, Tauben DJ, Rosenblatt R, Buchwald D, Doorenbos A, Towle C, Ramers CB, Spach DH. Project ECHO: A Model for Complex, Chronic Care in the Pacific Northwest of the United States. Journal of Telemedicine and Telecare 2012; 18(8):481-4. [original work]
10. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJeus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Favery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson I. Simeprevir plus sofosbuvir with/without ribavirin for treating chronic HCV genotype 1 infection in prior null-responders to peginterferon/ribavirin and treatment-naïve patients (COSMOS: a randomised study). Lancet 2014 Nov 15;384(9956):1756-65. [original work]
11. Siddiqui J, Herchline T, Kahlon SS, Moyer KJ, Scott JD, Wood BR, Young J. Infectious Diseases Society of America Position Statement on Telehealth and Telemedicine as Applied to the Practice of the Infectious Diseases. Clin Infect Dis 2017 Feb 1;64(3):237-242. doi: 10.1093/cid/ciw773. [review]
12. Chung RT, Ghany MG, Kim AY, Marks KM, Naggie S, Vargas HE, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Fontana RJ, Gordon SC, Heller T, Holmberg SD, Jhaveri R, Jonas M, Kiser JJ, Linas BP, Lo Re V, Morgan TR, Nahass RG, Peters M, Reddy KR, Reynolds A, Scott JD, Searson G, Swan T, Terrault NA, Trooskin SB, Wong JB, Workowski K. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018; 67(10):1477-92. https://doi.org/10.1093/cid/ciy585. [review]
13. Ansary A, Martinez J, Scott J. The Virtual Physical Exam in the 21st Century. J Telemed Telecare 2019 Nov 6;1357633X19878330. doi: 10.1177/1357633X19878330 [review]
14. Scott JD, et al. A Population--based Intervention to Improve Care Cascades of Patients with Hepatitis C Virus Infection. Hepatology Communications 2021; 5(3):387-99